Zymeworks Inc. Common Stock (ZYME) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zymeworks Inc. Common Stock stock (ZYME) is currently trading at $23.60. Zymeworks Inc. Common Stock PS ratio (Price-to-Sales) is 16.35. Analyst consensus price target for ZYME is $40.08. WallStSmart rates ZYME as Sell.
- ZYME PE ratio analysis and historical PE chart
- ZYME PS ratio (Price-to-Sales) history and trend
- ZYME intrinsic value — DCF, Graham Number, EPV models
- ZYME stock price prediction 2025 2026 2027 2028 2029 2030
- ZYME fair value vs current price
- ZYME insider transactions and insider buying
- Is ZYME undervalued or overvalued?
- Zymeworks Inc. Common Stock financial analysis — revenue, earnings, cash flow
- ZYME Piotroski F-Score and Altman Z-Score
- ZYME analyst price target and Smart Rating
Zymeworks Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Zymeworks Inc. Common Stock (ZYME) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Zymeworks Inc. Common Stock (ZYME) Key Strengths (1)
98.43% of shares held by major funds and institutions
Supporting Valuation Data
Zymeworks Inc. Common Stock (ZYME) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -91.90%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 16.4x annual revenue
Very expensive at 6.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Zymeworks Inc. Common Stock (ZYME) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (16.35), Price/Book (6.46) suggest expensive pricing. Growth concerns include Revenue Growth at -91.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -26.70%, Operating Margin at -1756.00%, Profit Margin at -76.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -91.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZYME Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZYME's Price-to-Sales ratio of 16.35x trades at a deep discount to its historical average of 33.12x (32th percentile). The current valuation is 87% below its historical high of 126.3x set in Nov 2020, and 1322% above its historical low of 1.15x in Sep 2023. Over the past 12 months, the PS ratio has expanded from ~12.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zymeworks Inc. Common Stock (ZYME) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Zymeworks Inc. Common Stock is in a turnaround phase, with management focused on restoring profitability. Revenue reached 106M with 92% decline year-over-year. The company is currently unprofitable, posting a -76.6% profit margin.
Key Findings
Spending 29% of revenue (31M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 92% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -76.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Zymeworks Inc. Common Stock.
Bottom Line
Zymeworks Inc. Common Stock is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zymeworks Inc. Common Stock(ZYME)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.